Natera's prenatal testing coverage expands

By staff writers

April 6, 2020 -- A national insurer has expanded coverage of Natera's Panorama cell-free DNA and noninvasive prenatal test to all pregnant women, regardless of age. Natera did not name the insurer.

The increased coverage comes after the Society for Maternal-Fetal Medicine recommended that prenatal office visits be reduced during the COVID-19 pandemic, Natera said. Panorama tests can be accessed through Natera without a live office visit, according to the firm.

Panorama tests for severe genetic disorders as early as nine weeks into pregnancy by analyzing fetal/placental DNA taken through a blood draw from the mother, the company said.

Natera releases pricing for Prospera cell-free DNA test
Cell-free DNA testing company Natera has released pricing for its Prospera donor-derived cell-free DNA organ transplant laboratory-developed test.
Natera evaluates serial cfDNA blood testing in colon cancer
Cell-free DNA (cfDNA) testing company Natera is launching a study this year of its Signatera blood test in patients with stage II/III colorectal cancer...
Liquid biopsy boosts the odds in triple-negative breast cancer
Circulating tumor DNA test results were significantly associated with disease-free survival in women with early triple-negative breast cancer in a phase...
Foundation, Natera join to develop ctDNA assays
Foundation Medicine and Natera are joining forces to develop and commercialize personalized circulating tumor DNA (ctDNA) monitoring assays.
Natera touts liquid biopsy in bladder cancer
Results from Natera's prospective study validating its Signatera circulating tumor DNA (ctDNA) test in urothelial bladder cancer were published online...

Copyright © 2020

Last Updated np 4/6/2020 12:19:22 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.